Acorda Therapeutics (ACOR) Misses Q1 EPS by 33c, Revenues Miss
Get Alerts ACOR Hot Sheet
Price: $0.66 --0%
EPS Growth %: -139.7%
Financial Fact:
Research and development: 54.78M
Today's EPS Names:
RBKB, BPRN, OFED, More
EPS Growth %: -139.7%
Financial Fact:
Research and development: 54.78M
Today's EPS Names:
RBKB, BPRN, OFED, More
Join SI Premium – FREE
Acorda Therapeutics (NASDAQ: ACOR) reported Q1 EPS of $0.14, $0.33 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $106.2 million versus the consensus estimate of $129.87 million.
Guidance for 2018
- The Company reiterates AMPYRA 2018 net revenue guidance of $330-$350 million. The Company expects to maintain exclusivity of AMPYRA at least through July 30, 2018; this guidance is subject to change based on the appellate court’s decision.
- R&D expenses for the full year 2018 are expected to be $100-$110 million and include manufacturing expenses associated with INBRIJA. This guidance is a non-GAAP projection that excludes share-based compensation, as more fully described below under “Non-GAAPFinancial Measures.”
- SG&A expenses for the full year 2018 are expected to be $170-$180 million. This guidance is a non-GAAP projection that excludes share-based compensation, as more fully described below under “Non-GAAP Financial Measures.”
- The Company expects to end 2018 with a projected year-end cash balance in excess of $300 million.
For earnings history and earnings-related data on Acorda Therapeutics (ACOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- TriNet Group (TNET) Misses Q1 EPS by 30c, Updates Guidance
- Codorus Valley Bancorp (CVLY) Misses Q1 EPS by 2c
- Heritage Commerce (HTBK) Misses Q1 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!